scholarly journals The Emerging Role of Gut Microbiota in Cardiovascular Diseases

2021 ◽  
Author(s):  
Dilip Kumar ◽  
Sanjeev S. Mukherjee ◽  
Rabin Chakraborty ◽  
Rana Rathod Roy ◽  
Arindam Pandey ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota

scholarly journals Implication of Gut Microbiota in Cardiovascular Diseases

2020 ◽  
Vol 2020 ◽  
pp. 1-14
Author(s):  
Wenyi Zhou ◽  
Yiyu Cheng ◽  
Ping Zhu ◽  
M. I. Nasser ◽  
Xueyan Zhang ◽  
...  
Keyword(s):  
Cell Death ◽  
Cardiovascular Diseases ◽  
Programmed Cell Death ◽  
Gut Microbiota ◽  
Intestinal Flora ◽  
Short Chain Fatty Acids ◽  
Secondary Bile Acid ◽  
Cardiac Disorders ◽  
The Relationship

Emerging evidence has identified the association between gut microbiota and various diseases, including cardiovascular diseases (CVDs). Altered intestinal flora composition has been described in detail in CVDs, such as hypertension, atherosclerosis, myocardial infarction, heart failure, and arrhythmia. In contrast, the importance of fermentation metabolites, such as trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), and secondary bile acid (BA), has also been implicated in CVD development, prevention, treatment, and prognosis. The potential mechanisms are conventionally thought to involve immune regulation, host energy metabolism, and oxidative stress. However, numerous types of programmed cell death, including apoptosis, autophagy, pyroptosis, ferroptosis, and clockophagy, also serve as a key link in microbiome-host cross talk. In this review, we introduced and summarized the results from recent studies dealing with the relationship between gut microbiota and cardiac disorders, highlighting the role of programmed cell death. We hope to shed light on microbiota-targeted therapeutic strategies in CVD management.

Pivotal Role Of The Interaction Between Herbal Medicines And Gut Microbiota On Disease Treatment

2020 ◽  
Vol 21 ◽  
Author(s):  
Tingting Zhao ◽  
Zhe Wang ◽  
Zhilong Liu ◽  
Youhua Xu
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Neurodegenerative Diseases ◽  
Disease Progression ◽  
Herbal Medicines ◽  
Underlying Mechanism ◽  
Disease Treatment ◽  
Endocrine Diseases ◽  
Health And Disease

: With the recognition of the important role of gut microbiota in both health and disease progression, attempts to modulate its composition as well as its co-metabolism with the organism have attracted special attention. Abundant studies have demonstrated that dysfunction or imbalance of gut microbiota is closely with disease including endocrine diseases, neurodegenerative diseases, tumors, cardiovascular diseases, et al. Herbal medicines have been applied for preventing and treating disease worldwide for hundreds of years. Although the underlying mechanism seems to be complex, one of the important one is through modulating gut microbiota. In this review, co-metabolism between herbal medicines and microbiota, as well as the potential pathways are summarized from most recent published papers.

scholarly journals Fat, Sugar or Gut Microbiota in Reducing Cardiometabolic Risk: Does Diet Type Really Matter?

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 639
Author(s):  
Katarzyna Nabrdalik ◽  
Katarzyna Krzyżak ◽  
Weronika Hajzler ◽  
Karolina Drożdż ◽  
Hanna Kwiendacz ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Cardiometabolic Risk ◽  
Saturated Fat ◽  
Lifestyle Changes ◽  
Dietary Guidelines ◽  
Factors Affecting ◽  
Cardiometabolic Diseases ◽  
Low Carbohydrate Diet

The incidence of cardiometabolic diseases, such as obesity, diabetes, and cardiovascular diseases, is constantly rising. Successful lifestyle changes may limit their incidence, which is why researchers focus on the role of nutrition in this context. The outcomes of studies carried out in past decades have influenced dietary guidelines, which primarily recommend reducing saturated fat as a therapeutic approach for cardiovascular disease prevention, while limiting the role of sugar due to its harmful effects. On the other hand, a low-carbohydrate diet (LCD) as a method of treatment remains controversial. A number of studies on the effect of LCDs on patients with type 2 diabetes mellitus proved that it is a safe and effective method of dietary management. As for the risk of cardiovascular diseases, the source of carbohydrates and fats corresponds with the mortality rate and protective effect of plant-derived components. Additionally, some recent studies have focused on the gut microbiota in relation to cardiometabolic diseases and diet as one of the leading factors affecting microbiota composition. Unfortunately, there is still no precise answer to the question of which a single nutrient plays the most important role in reducing cardiometabolic risk, and this review article presents the current state of the knowledge in this field.

scholarly journals Role of Gut Microbiota in the Pathogenesis of Cardiovascular Diseases and Metabolic Syndrome

2018 ◽  
Vol 14 (4) ◽  
pp. 567-574 ◽  
Author(s):  
O. M. Drapkina ◽  
O. E. Shirobokikh
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Fatty Acids ◽  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Bile Acids ◽  
G Protein ◽  
Short Chain Fatty Acids ◽  
Short Chain

The role of gut microbiota in the pathogenesis of cardiovascular diseases (CVD) and metabolic syndrome has attracted massive attention in the past decade. Accumulating evidence has revealed that the metabolic potential of gut microbiota can be identified as a contributing factor in the development of atherosclerosis, hypertension, heart failure, obesity, diabetes mellitus. The gut-host interaction occurs through many pathways including trimethylamine-N-oxide pathway (TMAO), short-chain fatty acids and second bile acids pathways. TMAO (the hepatic oxidation product of the microbial metabolite of trimethylamine) enhances platelet hyperreactivity and thrombosis risk and predicts major adverse cardiovascular events. Short-chain fatty acids and second bile acids, which are produced with the help of microbiota, can modulate host lipid metabolism as well as carbohydrate metabolism through several receptors such as G-protein-coupled receptors 41,43, farnesoid X-receptor, Takeda-G-protein-receptor-5. This way microbiota can impact host lipid levels, processes of weight gain, insulin sensitivity. Besides these metabolism-dependent pathways, there are some other pathways, which link microbiota and the pathogenesis of CVD. For example, lipopolysaccharide, the major component of the outer bacterial membrane, causes metabolic endotoxemia and low-grade systemic inflammation and contribute this way to obesity and progression of heart failure and atherosclerosis. This review aims to illustrate the complex interplay between microbiota, their metabolites, and the development and progression of CVD and metabolic syndrome. It is also discussed how modulating of gut microbiota composition and function through diet, prebiotics, probiotics and fecal microbiota transplantation can become a novel therapeutic and preventative target for CVD and metabolic syndrome. Many questions remain unresolved in this field and undoubtedly further studies are needed.

scholarly journals The Effective Role of Natural Product Berberine in Modulating Oxidative Stress and Inflammation Related Atherosclerosis: Novel Insights Into the Gut-Heart Axis Evidenced by Genetic Sequencing Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Richard Y. Cao ◽  
Ying Zhang ◽  
Zhen Feng ◽  
Siyu Liu ◽  
Yifan Liu ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Natural Product ◽  
Sequencing Analysis ◽  
Inflammatory Reactions ◽  
Genetic Sequencing ◽  
Effective Role ◽  
Underlying Mechanisms ◽  
Atherosclerotic Cardiovascular Diseases

The exacerbation of oxidative and inflammatory reactions has been involved in atherosclerotic cardiovascular diseases leading to morbidity and mortality worldwide. Discovering the underlying mechanisms and finding optimized curative approaches to control the global prevalence of cardiovascular diseases is needed. Growing evidence has demonstrated that gut microbiota is associated with the development of atherosclerosis, while berberine, a natural product exhibits antiatherogenic effects in clinical and pre-clinical studies, which implies a potential link between berberine and gut microbiota. In light of these novel discoveries, evidence of the role of berberine in modulating atherosclerosis with a specific focus on its interaction with gut microbiota is collected. This review synthesizes and summarizes antioxidant and anti-inflammatory effects of berberine on combating atherosclerosis experimentally and clinically, explores the interaction between berberine and intestinal microbiota comprehensively, and provides novel insights of berberine in managing atherosclerotic cardiovascular diseases via targeting the gut-heart axis mechanistically. The phenomenon of how berberine overcomes its weakness of poor bioavailability to conduct its antiatherogenic properties is also discussed and interpreted in this article. An in-depth understanding of this emerging area may contribute to identifying therapeutic potentials of medicinal plant and natural product derived pharmaceuticals for the prevention and treatment of atherosclerotic cardiovascular diseases in the future.

scholarly journals The role of gut microbiota in cardiovascular diseases

2018 ◽  
Vol 75 (2) ◽  
pp. 213-224
Author(s):  
Zinnet Şevval Aksoyalp ◽  
Cahit Nacitarhan
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota

scholarly journals POTENTIAL ROLE OF GUT MICROBIOTA IN OBESITY AND CARDIOVASCULAR DISEASES

2021 ◽  
Vol 54 (3) ◽  
pp. 207-213
Author(s):  
Sana Ashiq ◽  
Kanwal Ashiq
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Metabolic Disorders ◽  
Potential Role ◽  
Immune Homeostasis ◽  
Mortality And Morbidity ◽  
The Past ◽  
Dietary Components ◽  
Insight Into

From the past several decades to the present, obesity and cardiovascular diseases emerge as a major cause of mortality and morbidity, ultimately imposing a huge economic burden globally. In humans, a healthy gut microbiota metabolizes several indigestible dietary components which maintain host immune homeostasis, but an imbalanced host-microbiota is associated with various metabolic disorders including cardiovascular diseases and obesity. In this present review, we critically analyze the literature which provides better insight into the mechanistic link of gut microbiota with obesity and cardiovascular diseases. There is strong evidence that suggests the potential role of the gut microbiota in metabolic disorders including cardiovascular diseases and obesity. In addition, the different studies report that gut microbes can play a promising role in the management of obesity and the treatment of cardiovascular diseases. In the future, multidisciplinary approaches and advancements in culturing and molecular biology techniques can provide us a better understanding.

scholarly journals Role of gut microbiota in cardiovascular diseases

2020 ◽  
Vol 12 (4) ◽  
pp. 110-122 ◽  
Author(s):  
Marko Novakovic ◽  
Amit Rout ◽  
Thomas Kingsley ◽  
Robert Kirchoff ◽  
Amteshwar Singh ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota

Yellow Wine Polyphenolic Compound Protects Against Doxorubicin-Induced Cardiotoxicity by Modulating the Composition and Metabolic Function of the Gut Microbiota

2021 ◽  
Author(s):  
Hui Lin ◽  
Liping Meng ◽  
Zhenzhu Sun ◽  
Shiming Sun ◽  
Xingxiao Huang ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Gas Chromatography Mass Spectrometry ◽  
Dependent Manner ◽  
Polyphenolic Compound ◽  
Dietary Polyphenols ◽  
Microbial Dysbiosis ◽  
Myocardial Apoptosis ◽  
Rdna Sequencing

Background: Dietary polyphenols help to prevent cardiovascular diseases, and interactions between polyphenols and gut microbiota are known to exist. In this study, we speculated that gut microbiota-mediated metabolite regulation might contribute to the anticardiotoxic effects of yellow wine polyphenolic compound (YWPC) in doxorubicin (DOX)-treated rats. Methods: 16S-rDNA sequencing was performed to analyze the effects of YWPC on the gut microbiota in DOX-treated rats (n=6). Antibiotics were used to investigate the contribution of the altered microbiome to the role of YWPC (n=6). Plasma metabolomics were also analyzed by untargeted gas chromatography-mass spectrometry systems. Results: YWPC ameliorated DOX-mediated cardiotoxicity, as evidenced by increased cardiac and mitochondrial function and reduced levels of inflammation and myocardial apoptosis ( P <0.05 for all). The low abundance of Escherichia – Shigella , Dubosiella , and Allobaculum , along with enrichment of Muribaculaceae_unclassified , Ralstonia , and Rikenellaceae_RC9_gut_group in the gut, suggested that YWPC ameliorated DOX-induced microbial dysbiosis. YWPC also influenced the levels of metabolites altered by DOX, resulting in lower arachidonic acid and linoleic acid metabolism and higher tryptophan metabolite levels ( P <0.05 for all). Correlational studies indicated that YWPC alleviated DOX-induced inflammation and mitochondrial dysfunction by modulating the gut microbial community and its associated metabolites. Antibiotic treatment exacerbated cardiotoxicity in DOX-treated rats, and its effect on the gut microbiota partly abolished the anticardiotoxic effects of YWPC, suggesting that the microbiota is required for the cardioprotective role of YWPC. Conclusions: YWPC protected against DOX-induced cardiotoxicity in a gut microbiota–dependent manner. This supports the use of dietary polyphenols as a therapeutic approach for the treatment of cardiovascular diseases via microbiota regulation.

Sign in / Sign up

Export Citation Format

Share Document